Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 14/20 | 0.42 |
| ▸ | MAPK13 | O15264 | 6/20 | 0.42 |
| ▸ | MAPK12 | P53778 | 6/20 | 0.42 |
| ▸ | MAPK11 | Q15759 | 6/20 | 0.42 |
| ▸ | GCGR | P47871 | 2/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
| ▸ | HMGCR | P04035 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7090794 | 0.89 | MAPK14 (0.43) | MAPK14MAPK13MAPK12MAPK11GCGR | |
| SCHEMBL11178939 | 0.83 | PTGS2 (0.38) | — | |
| SCHEMBL7088083 | 0.81 | MAPK14 (0.43) | MAPK14MAPK13MAPK12MAPK11GCGR | |
| SCHEMBL9006002 | 0.74 | HMGCR (0.41) | MAPK14MAPK13MAPK12MAPK11FAAH | |
| SCHEMBL7084889 | 0.72 | MAPK14 (0.51) | MAPK14MAPK13MAPK12MAPK11GCGR | |
| SCHEMBL7084428 | 0.72 | MAPK14 (0.51) | MAPK14MAPK13MAPK12MAPK11GCGR | |
| SCHEMBL7090577 | 0.70 | MAPK14 (0.35) | MAPK14MAPK13MAPK12MAPK11GCGR | |
| SCHEMBL7090578 | 0.69 | MAPK14 (0.42) | MAPK14MAPK13MAPK12MAPK11GCGR | |
| SCHEMBL8801695 | 0.67 | CYP1A2 (0.30) | — | |
| SCHEMBL7084443 | 0.64 | PTGS2 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030050330-A1 | 4,5-subtstituted imdazolyl compounds for the treatment of inflammation | G.D. SEARLE & CO. | 2003-03-13 | — | — | US | disclosed |
| EP-0772601-B1 | 4,5-SUBSTITUTED IMIDAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | SEARLE & CO (US) | 2002-09-18 | — | — | EP | disclosed |
| US-6426360-B1 | ANTIARTHRITIC AGENTS | G D SEARLE & CO. | 2002-07-30 | — | — | US | disclosed |
| EP-1211244-A2 | 4,5-substitued imidazolyl compounds for the treatment of inflammation | G.D. Searle & Co. (US) | 2002-06-05 | — | — | EP | disclosed |
| EP-0772601-A1 | 4,5-SUBSTITUTED IMIDAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1997-05-14 | — | — | EP | disclosed |
| WO-1996003387-A1 | 4,5-SUBSTITUTED IMIDAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030050330-A1 | 4,5-subtstituted imdazolyl compounds for the treatment of inflammation | AHR, HACL2, IRAK2 | MAPK14 1523/4885MAPK13 2251/4885MAPK12 2078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.